Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

12.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 3 Next >

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

September 18, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at September Investor Conferences

August 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 19, 2025

Via Benzinga

Contineum (CTNM) Q2 R&D Jumps 78% ↗

August 05, 2025

Via The Motley Fool

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

August 05, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

June 25, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

May 14, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

April 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

March 17, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

March 12, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

March 06, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

March 04, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

March 03, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 21, 2025

Via Benzinga

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

January 08, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

January 06, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

December 16, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗

December 12, 2024

Via Benzinga

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

November 25, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

November 18, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Attend Upcoming Investor Conferences

November 13, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 06, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

August 28, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024 ↗

August 13, 2024

CTNM stock results show that Contineum Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 13, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

July 31, 2024

From Contineum Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.